Halozyme Therapeutics, Inc. vs Johnson & Johnson
HALO vs JNJ — side-by-side comparison from reported financials. HALO leads 5, JNJ leads 5 of 10 comparable metrics.
Halozyme Therapeutics, Inc.
HALO · Healthcare
$111.35+1.38%Mixed
Johnson & Johnson
JNJ · Healthcare
$261.79+2.07%Mixed
| Metric | HALO | JNJ |
|---|---|---|
| Price | $111.35 | $261.79 |
| Market cap | $12.6B | $631B |
| Revenue (TTM) | $1.66B | $97.9B |
| Revenue growth | +28.4% | +5.6% |
| Net margin | 24.9% | 21.5% |
| Free cash flow | $806M | $22.2B |
| Net cash (debt) | ($2.01B) | ($27.8B) |
| 1-year price return | +71.0% | +37.0% |
| P/E | 30.3 | 29.9 |
| P/E vs own history (cheap-side %) | 8% | 16% |
| Dividend yield | — | 2.00% |
| Return on equity | 181% | 26% |
| CV checks passed | 9 of 10 | 10 of 10 |
| Employees | 423 | 140,800 |
Full résumé-style profiles: HALO CV · JNJ CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.